At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 16 Sep 1996 Discontinued-Preclinical for Inflammation in Germany (Unknown route)
- 21 Jul 1995 No-Development-Reported for Inflammation in Germany (Unknown route)